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BLR1 and FCGR1A transcripts in 
peripheral blood associate with the 
extent of intrathoracic tuberculosis 
in children and predict treatment 
outcome
Synne Jenum1,2, Rasmus Bakken1,*, S. Dhanasekaran1,*, Aparna Mukherjee3, Rakesh Lodha3, 
Sarman Singh4, Varinder Singh5, Marielle C. Haks6, Tom H. M. Ottenhoff6, S. K. Kabra3, 
T. Mark Doherty7, Christian Ritz8 & Harleen M. S. Grewal1,9
Biomarkers reflecting the extent of Mycobacterium tuberculosis-induced pathology and normalization 
during anti-tuberculosis treatment (ATT) would considerably facilitate trials of new treatment regimens 
and the identification of patients with treatment failure. Therefore, in a cohort of 99 Indian children 
with intrathoracic tuberculosis (TB), we performed blood transcriptome kinetic analysis during ATT to 
explore 1) the association between transcriptional biomarkers in whole blood (WB) and the extent of TB 
disease at diagnosis and treatment outcomes at 2 and 6 months, and 2) the potential of the biomarkers 
to predict treatment response at 2 and 6 months. We present the first data on the association between 
transcriptional biomarkers and the extent of TB disease as well as outcome of ATT in children: 
Expression of three genes down-regulated on ATT (FCGR1A, FPR1 and MMP9) exhibited a positive 
correlation with the extent of TB disease, whereas expression of eight up-regulated genes (BCL, 
BLR1, CASP8, CD3E, CD4, CD19, IL7R and TGFBR2) exhibited a negative correlation with the extent of 
disease. Baseline levels of these transcripts displayed an individual capacity >70% to predict the six-
month treatment outcome. In particular, BLR1 and FCGR1A seem to have a potential in monitoring and 
perhaps tailoring future antituberculosis therapy.
The emerging epidemic of multi-drug resistant tuberculosis (MDR-TB) calls for new treatment strategies. 
Biomarkers reflecting the extent of Mycobacterium tuberculosis (Mtb) induced pathology and normaliza-
tion during anti-tuberculosis treatment (ATT) would considerably facilitate trials of new treatment regi-
mens and the identification of patients with treatment failure1. The current tools for monitoring treatment 
of pulmonary TB are limited to clinical assessments of signs/symptoms, assessment of regular inflam-
matory markers (erythrocyte sedimentation rate, C-reactive protein and white blood cells), radiological 
changes, and repeated sampling of respiratory specimen to detect the presence of Mtb and their viability. 
The conversion of positive to negative Mtb-culture after 2 months treatment is the only validated predic-
tor of the required duration of treatement and the risk of relapse2. Notably, this biomarker has evident lim-
itations in children as only 30% of TB cases are culture positive at diagnosis. Recent evidence suggests that 
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blood transcriptomes are sensitive markers of immunological changes as early as 1–2 weeks after initiation 
of ATT3–5. At diagnosis, TB patients are highly diverse when it comes to the manifestations and extent of 
disease which to some degree is reflected in smear positivity, Mtb-culture positivity, cavitating disease and 
weight, all prognostic factors of treatment response. There is a substantial body of evidence that the greater 
the extent of TB disease and the bacterial load in the sputum at diagnosis, the higher the risk for treatment 
failure or relapse2,6,7. Therefore, biomarkers which reflect the extent of disease are likely to have a potential to 
predict the ATT treatment outcome relevant to adequate individual management and prevention of multi-drug 
resistance. Genome-wide analysis of transcriptomes are increasingly applied in studies aiming to identify 
diagnostic and predictive biomarkers relevant to TB management. Surprisingly, except for Anderson et al.  
who addressed disease extent in pediatric TB according to a diagnostic algorithm that takes into account the 
high number of unconfirmed cases8, the association between transcripts that change on treatment and the 
extent of TB disease at diagnosis and end of treatment has not been systematically addressed3,9.
Therefore, within the setting of a randomized, double-blind, placebo-controlled longitudinal trial (rct) car-
ried out to assess the effect of micronutrient supplementation in children with intrathoracic TB treated with 
ATT10, the present study was set up to explore 1) the association between transcriptional and translational 
biomarkers in WB and the extent of TB disease at diagnosis and treatment outcomes at 2 and 6 months, and 2) 
the potential of the biomarkers to predict treatment response at 2 and 6 months. Furthermore, we wanted to 3) 
explore eventual sub-clinical effects of micronutrient supplementation on immune transcripts with likely rel-
evance in TB disease. The rationale for this was that despite clear scientific evidence that malnutrition and 
micronutrient deficiency are judged important risk factors for TB11,12, our original intervention trial10 and 
similar studies in other populations13, indicated that micronutrient supplementation does not seem to improve 
the clinical outcome of ATT significantly10. The reasons for this are unclear and may be due to the fact that 
micronutrient deficiency associated with malnutrition is only one factor, and may be correlated with, rather 
than causal for, the elevated risk. Unlike similar studies adressing the effect of micronutrient supplementation 
in adults14–19 and children20 treated for TB, sample collection in our original intervention trial10 allowed for 
detailed biomarker analyses.
Results
Demographic and clinical characteristics. Of the 99 children consenting to this cross-sectional study 
nested within a micronutrient intervention trial10 (Fig. 1), 49 had intrathoracic TB primarily as a result of pro-
gressive primary disease and 17 had uncomplicated lymphadenopathy. Cavities were described in 10 patients, 
whereas one child had miliary TB. Forty one children had Mtb verified by culture. Overall, the presentation and 
localization of TB disease in the children reflected the age distribution in the cohort; 83 children being > 5 years21. 
Detailed description of the clinical characteristics are given in Table 1. There were no differences in demographic 
or clinical characteristics between the four micronutrient treatment groups at baseline, but a difference in the 
proportion of QFT positive children was found (micronutrient: 87%; micronutrient + Zinc: 50%; Zinc: 91.3%; 
placebo: 66.7%, p = 0.011).
Effect of micronutrient supplements on immune biomarkers relevant in TB. As large dif-
ferences in immune biomarker levels between the intervention groups would complicate the interpreta-
tion of ATT related changes, we started out by assessing changes in host transcriptional and proteomic 
biomarkers over time and differences between the treatment groups after 2 months of treatment (Fig. 2, 
Supplementary Table 1A). Although no specific biomarker pattern was found to be associated with micronu-
trient or zinc supplementation, 11 transcriptional biomarkers changed consistently in all groups: 3 genes were 
down-regulated (FCGR1A, FPR1 and MMP9) and 8 genes were up-regulated (BCL, BLR1, CASP8, CD3E, CD4, 
CD19, IL7R and TGFBR2) (Fig. 2). With regard to the soluble cytokine biomarkers tested in stimulated WB, 
no significant changes were found across the groups (Supplementary Table 1B,C). This suggests the changes 
observed were driven by ATT rather than the trial-specific micronutrient interventions, justifying further 
exploration of the association between immune biomarkers and the extent of TB disease at diagnosis and 
treatment outcomes in the whole cohort.
Are biomarkers that change consistently over the course of treatment associated with the 
extent of TB disease? We then investigated the association between the baseline levels of the 11 transcrip-
tional biomarkers associated with the parameters of disease extent (smear and culture positivity, cavitating dis-
ease and weight). All the 11 transcripts correlated to at least one of the modalities for disease extent. The levels of 
the biomarkers FCGR1A, FPR1 and MMP9, correlated positively with disease extent at baseline and declined on 
treatment. Correspondingly, biomarkers that correlated negatively with disease extent at baseline (BCL, BLR1, 
CASP8, CD3E, CD4, CD19, IL7R and TGFBR2) increased on treatment, which might suggest that these markers 
are indicative of reconstituted immunity, or decreased pathology. Interestingly, BLR, CD3E, and IL7R associated 
with all the investigated parameters for disease extent (Table 2). No association with disease extent was found for 
the level of protein expression of IFNγ and IL-2, in response to stimulation with Mtb-specific antigens. Adjusting 
for age did not significantly influence on these associations except for MMP9 which lost the association with Mtb 
culture positivity and cavitating disease.
Do biomarkers that reflect the extent of TB disease associate with treatment outcomes? In 
most TB patients, there is a gradual resolution of TB-related pathology on ATT. With evidence of clear association 
between 11 transcriptional biomarkers and the extent of TB disease in our cohort, we investigated the association 
of the biomarkers measured at baseline, after 2 months as well as the change from baseline to 2 months, with pre-
viously defined treatment outcomes at 2 and 6 months. Out of the 11 tested transcripts, only BLR1 and FCGR1A 
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had a significant association (Table 2): At baseline, every log unit increase in baseline BLR1-levels decreased the 
likelihood for an unfavourable outcome at 2 months by 30% (ORBLR1 0.70, 95%CI[0.50;0.98]), but at the same 
time, an increase in BLR1-levels from baseline to 2 months increased the likelihood for an unfavourable outcome 
with borderline significance (ORBLR1 1.77, 95%CI[1.00;3.13]), which likely reflects a steeper increase in BLR1 
levels on treatment in children with low levels at baseline - possibly indicative of severe disease. For every log 
unit increase in FCGR1A-levels at 2 months the likelihood for an unfavourable treatment outcome at 6 months 
doubled (ORFCGR1A 2.11, 95%CI[1.03;4.31]).
Adjusting for age at baseline did not influence on these associations. The distribution of treatment outcomes 
at 2 and 6 months in the study subjects are listed in Table 3.
Do biomarkers that reflect the extent of TB disease predict treatment outcomes? We therefore 
examined the predictive capacity of the 11 transcriptional biomarkers measured at baseline, after 2 months as well 
as the change from baseline to 2 months, for treatment outcomes at 2 and 6 months (Table 4). The cross-validation 
estimate for accuracy was best for baseline biomarker measurements and > 70% for all genes except CD4 (68%). 
BCL2, CASP8, IL7R and TGFBR2 each had a predictive capacity of ≥ 75%. Both BLR1 and FCGR1A associated 
with treatment outcomes and together their predictive capacity was 71.4%. The predictive capacity was not fur-
ther increased by entering all the 11 biomarkers in the model. Likewise, testing predictive capability for treatment 
outcomes at 2 and 6 months by jointly entering all transcriptional biomarkers with detectable levels (20 out of 
Figure 1. Flowchart of sample selection from ¹the randomized-controlled trial (rct) of the effect of different 
micronutrient (MN) supplementation on top of anti-tuberculosis therapy (ATT). As part of the ATT rct, 
included children were assigned to 4 intervention groups; micronutrient supplementation (MN) with or without 
zinc (Zn), Zn alone or placebo, and followed for 6 months10. Samples available for transcriptional biomarker 
studies from each intervention-group at baseline, and after 2 and 6 months of treatment are depicted in the table. 
*The sampling for the present biomarker study were possible after approval of a study amendment during the 
on-going inclusion to the mother study. Participation in the present add-on study required an additional consent 
at each study visit for additional biomarker study-specific blood-draws. This explains why 88 and not all of the 
99 children have a baseline sample, and the successive loss of available samples for transcriptional biomarker 
studies. Altogether, 163 samples were available. The distribution of samples at baseline, and after 2 and 6 months of 
treatment from each intervention group, are depicted in the table for clarity.
www.nature.com/scientificreports/
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49, excluding the house-keeping gene GAPDH) into the model without making any a priori assumptions, did not 
yield any additional significant correlations. Adjusting for age at baseline slightly reduced the predictive capacity.
Baseline characteristics Distribution
Sociodemographics and medical history
 Gender Male (n) 45
 Age mean age in months (St.dev) 107,8 (46,0)
≤5 years (n) 16
>5 to ≤10 years (n) 40
>10 to 16 years (n) 43
 Known contact with TB patient (n) 35
 BCG vaccination
Yes (n) 82
No (n) 16
Not known (n) 1
Symptoms
 Cough ≥ 2 weeks (n) 63
 Fever (n) 77
 Weight loss (n) 74
 Loss of appetite (n) 74
Anthropometric data
 Body Mass Index Z-score, mean (St.dev) − 2,28 (1,46)
 Weight-for-age Z-score, mean (St.dev) − 2,54 (1,68)
Diagnosis and treatment
 Smear positivityˇ (n) 13
 Mtb-culture positive° (n) 41
 NTM culture positivea (n) 7
 Finding on Chest X-ray
uncomplicated LN disease (n) 17
LN disease with collapse (n) 2
progressive primary disease (n) 49
primary pulmonary complex (n) 11
miliary TB (n) 1
pleural effusion (n) 8
cavitation disease (n) 10
calcification (n) 1
 Lymph node swelling (n) 19
 Tuberculin Skin Test
mean in mm (St.dev) 15,1 (8,1)
≥10 mm (n) 96
 QuantiFERON Gold In-tube
Positive (n) 76
Negative (n) 22
Indeterminate (n) 1
 Anti-tuberculosis treatment
Category 1b (n) 75
Category 3c (n) 24
 Micronutrient supplement
Micronutrients and Zinc (n) 25
Micronutrients (n) 21
Zinc (n) 26
Placebo (n) 27
Table 1. Demographic and clinical baseline characteristics of 99 children with intra-thoracic TB and 
samples analyzed for transcriptional biomarkers (dcRT-MLPA). Of 2 induced sputum samples and 2 
gastric aspirate samples taken on 2 consecutive days at least ˇone specimen positive for acid-fast bacilli, °one 
culture samples with growth of Mycobacterium tuberculosis or aNon-tuberculous mycobacteria. b2 months with 
isoniazid, rifampicin, pyrazinamide and etambuthol followed by 4 months of isoniazid, rifampicin. c2 months 
with isoniazid, rifampicin and pyrazinamide followed by 4 months of 2 drugs.
www.nature.com/scientificreports/
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Discussion
In this cohort of 99 Indian children treated for intra-thoracic TB, we report on 11 transcriptional immune bio-
markers which changed consistently through the intensive phase of ATT. The three genes for which expression 
was down-regulated during treatment (FCGR1A, FPR1 and MMP9) exhibited a positive correlation with the 
extent of TB disease indicating that higher levels of these transcripts probably reflect the extent of TB-induced 
pathology, and may be indicative of bacterial load. The 8 genes that were up-regulated during treatment (BCL, 
BLR1, CASP8, CD3E, CD4, CD19, IL7R and TGFBR2) exhibited a negative correlation with the extent of TB dis-
ease, strongly suggesting that lower levels of transcripts reflect a greater degree of TB-induced pathology. Whereas 
only BLR1 and FCGR1A expression levels were associated with treatment outcomes at both 2 and 6 months, all 
11 biomarkers measured at baseline showed an individual capacity exceeding 70% to predict the ATT treatment 
outcome at 6 months. The predictive capacity of single genes did not increase when entering all 11 markers into 
the leave-10-out cross validation model, suggesting that their level of expression may be driven by similar events.
This study was nested within a larger study which explored the effect of different micronutrient supplementa-
tions on biomarkers of TB host immunity. However, we were unable to identify any specific effects – instead the 
changes in expression detected were overwhelmingly linked to the initiation of, and response to, ATT. It is unclear 
whether this failure to detect a signal is because any effects from micronutrient supplementation were below the 
threshold of detection by this study approach, or due to the biomarkers selected being sub-optimal for detecting 
the effect of micronutrients on host immune responses, or to limited sample size.
Previous studies have explored changes in transcriptional biomarkers on ATT in adults2–5,22–25 but studies in 
children are limited5,26. Research for predictive markers of treatment response is driven by the few tools available 
to guide decision-making during the prolonged course of ATT2. Notably, the only generally-accepted marker for 
treatment failure currently is lack of culture conversion at 2 months27. However, in addition to requiring weeks to 
get a final negative culture result, this parameter is of no use in the 70% pediatric TB cases that are culture nega-
tive at diagnosis28, thus leaving us with no tools to assess the early response to ATT in children. It is possible that 
specific host immune factors present during these first 2 months or even before the initiation of treatment, may 
help predicting treatment outcomes. Identification of such objectively-measured factors could pave the way for 
tailored individual treatment as well as facilitate the evaluation of the ongoing and planned studies of new treat-
ment regimens in children29. The present study is the first to directly assess how a panel of biomarkers associate 
with established parameters of TB disease extent and treatment outcomes in children. The reported consistencies 
between biomarkers and the extent of disease provide evidence for the assumption that the measured transcripts 
are biomarkers which truly reflect ongoing Mtb-related pathology. Treatment success is the key in limiting the 
emerging epidemic of multi-drug resistant TB, and depends on close monitoring of possible treatment failure or 
relapse. Biomarkers with a capacity to predict treatment response could enable more targeted use of limited health 
care resources to persons at risk. The impact on clinical management would be greatest for biomarkers with a 
predictive potential when measured at the initiation of treatment22. In the present study, ten out of 11 transcrip-
tional biomarkers predicted the treatment outcome at 6 months with an accuracy above 70%. CASP8, FPR1, IL7R 
Figure 2. Eleven transcripts were consistently down-regulated (blue) or up-regulated (red) across all 
study arms. The numbers represents the mean fold changes in relative gene expression levels from baseline to 2 
months of treatment, also visualized by color codes. 95% confidence intervals are given in parentheses.
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and TGFRB2 each had a predictive accuracy of ≥ 75% in a leave-10-out cross validation. Notably, baseline levels 
and changes in expression of BLR1 and FCGR1 were associated with treatment outcomes after 6 months, when 
assessed by logistic regression.
We report a positive correlation between the FCGR1A-levels at baseline and the extent of TB disease when 
assessed by smear or Mtb-culture positivity, or caviting disease. Primate models suggest that the extent of TB 
disease is closely correlated with bacterial load30. Furthermore, FCGR1A decreased with treatment, but for every 
log unit of decrease in FCGR1A at 2 months we observed a doubled likelihood for an unfavourable outcome at 6 
months. FCGR1A is an interferon-inducible gene highly expressed by myeloid cells like macrophages and neutro-
phils. Our findings are consistent with increasingly strong evidence of an up-regulation of interferon-inducible 
genes in TB patients4,8,24,31–33 and decline during treatment. A decline in FCGR1A-levels following treatment ini-
tiation has also been reported by others9. Notably, FCGR1A has also been shown to have a diagnostic potential for 
TB disease in various populations32,34,35, including children25,36 and is robust even in HIV co-infected subjects32,34. 
Very recently, FCGR1A was included in a 16-gene signature that predicted TB progression in latently infected 
individuals with a sensitivity of 71.2% within the 6–12 months preceding active TB disease25. Indeed, markers 
with a classifying potential in both diagnosis and prediction of treatment outcome are highly interesting for future 
point-of-care (POC) tools in order to facilitate both diagnosis and real-time evaluation of treatment response.
Interestingly, some of the biomarkers which associated with the extent of TB disease that changed consistently 
with treatment in the present study, are typically thought of as markers of B-cell mediated immunity: BLR1, CD19 
and FCGR1A. (Supplementary Table 1). Although the FCGR1A gene encodes the receptor which mediates the 
effect of binding of the Fc-region of Ig-G on B-cells, the contribution to the FCGR1A level in peripheral blood in 
the setting of TB is probably mostly due to a high expression on myeloid cells24 as previously discussed. B-cells 
were not given much attention in TB pathogenesis until Ulrichs and Kaufmann described the emergence of 
tertiary lymphoid structures in the vicinity of lung granulomas of TB patients37. The interest increased when 
Berry et al.24. revealed decreased abundance of B-cell transcripts in the RNA signature of TB patients, which 
has later been supported by others33,38,39. A recent publication also found an increase in the expression of B-cell 
markers from 4 to 26 weeks of ATT3.
Of the other 11 transcripts that consistently changed with treatment, an increase in CD19 expression on treat-
ment has also been described by others3,9. Interestingly, of the markers of disease extent investigated here, CD19 
only exhibited a small positive correlation with the BMIZ-score.
Unbiased RNA sequencing may offer some advantage compared with the dcRT-MLPA method. The 
dcRT-MLPA method was however, chosen for its suitability for low-cost hypothesis-testing of biomarkers 
identified as a result of joint efforts in TB biomarker discovery by the partners in Bill and Melinda Gates foun-
dation (GC6). The genes previously identified, have shown differential expression between TB patients, and 
healthy subjects with or without latent Mtb infection (LTBI), either in studies based on unbiased approaches 
or biased approaches where the markers were selected for their known/suggested role in TB pathogenesis 
(Supplementary Table 2). Moreover, the low volume of sample material required for the dcRT-MLPA was also 
an important consideration important given the limited amount of sample drawn per child per time-point9,40. 
As we did not apply any multiplicity adjustment of p-values there is an increased risk of reporting false positive 
findings, but this approach was deliberately chosen to reduce the risk that we might overlook any potential asso-
ciations. Although age adjustments slightly reduced the predictor capacity of the single transcripts and signatures 
BM change 
with 
treatment
BM entered 
in the model
Smear positivityˇ Mtb culture positive° Cavitating disease
Body Mass Index 
Z-score <−2
Body Mass 
Index Z-score, 
continous scale
Association with 
treatment outcomes
OR 95% CI for OR OR 95% CI for OR OR 95% CI for OR OR 95% CI for OR Rho p 2 months 6 months
Decrease
FCGR1A ns 3,14 (1,584–6,21) ns ns ns YESa YESa
FPR1 9,78 (2,09–45,8) ns ns 2,83 (1,13–7,14) ns ns ns
MMP9 ns 1,44 (1,02–2,03) 1,82 (1,06–3,12) ns –0,24 0,024 ns ns
Increase
BCL2 0,3 (0,1–0,92) ns 0,12 (0,03–0,49) ns ns ns ns
BLR1 0,47 (0,32–0,70) 0,46 (0,28–0,74) 0,5 (0,33–0,74) ns 0,24 0,026 YESb ns
CASP8 ns ns 0,13 (0,03–0,68) ns ns ns ns
CD3E 0,42 (0,23–0,78) 0,55 (0,33–0,92) 0,38 (0,20–0,75) ns 0,23 0,037 ns ns
CD4 0,37 (0,18–0,78) ns 0,45 (0,23–0,88) ns ns ns ns
CD19 ns ns ns ns 0,22 0,043 ns ns
IL7R 0,25 (0,11–0,56) 0,38 (0,21–0,69) 0,22 (0,09–0,53) ns 0,22 0,04 ns ns
TGFBR2 0,22 (0,05–0,94) 0,11 (0,03–0,37) 0,02 (0,003–0,19) ns ns ns ns
Table 2. Associations between baseline measurements of each of the 11 biomarkers (BM) that consitently 
changed with ATT and the extent of TB disease at the time of diagnosis (before the initiation of treatment). 
Of 2 induced sputum samples and 2 gastric aspirate samples taken on 2 consecutive days at least ˇone specimen 
positive for acid-fast bacilli, °one culture samples with growth of Mycobacterium tuberculosis. a2-month 
FCGR1A-value; positive association, details given in the text. bBaseline BLR1-value; negative association, and 
change from BL to 2 months; positive association, details given in the text. Unadjusted odds ratio estimates and 
95% confidence intervals is given for categorical variables and Spearman’s Rho and corresponding p-value is 
given for continous variables. ns signifies non-significant associations.
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tested, it had minor effect on the associations with TB disease extent and treatment outcome. This is indeed 
encouraging as immunological diagnostics are well known to be less reliable in young children41, and the fact 
that, diagnostic or monitoring tools requiring age adjustments complicates future clinical application. There is 
also a possibility that the reported changes, the correlations with the extent of TB disease and the predictive 
capacities of the identified transcripts discovered here are cohort-specific. Because of these limitations, the results 
need to be further evaluated and confirmed. Nonetheless, the consistent evidence for FCGR1A as a biomarker of 
the extent of TB disease is consistent across many studies, especially as previous studies have been done mostly 
in African cohorts of adolescents and adults, whereas the present study adds valuable evidence of relevance in 
Indian children.
Whereas, previous studies have explored the changes in transcriptional biomarkers on ATT, the present study 
is the first to directly assess how the biomarkers associate with established parameters of TB disease extent and 
treatment outcomes in children. Measured directly ex-vivo by a robust, accurate and cheap high-throughput tech-
nique, we found that low levels of BLR1 at baseline were indicative of more severe TB disease and increased the 
likelihood of an unfavourable treatment outcome at 2 months. High levels of FCGR1A measured after 2 months 
increased the likelihood of an unfavourable treatment outcome at 6 months. Together, these markers could serve 
as monitoring and predictive markers of treatment response to optimize the individual treatment and minimize 
the risk of relapse.
Materials and Methods
Source population. This study was cross-sectional and nested within a randomized, double-blind prospec-
tive controlled trial conducted from January 2008 to June 2012 at the All India Institute of Medical Sciences and 
Kalawati Saran Children Hospital associated with Lady Hardinge Medical College in Delhi, India for which the 
study details are described elsewhere10. Briefly, children aged 6 months to 15 years who presented with any of: 
cough and/or fever > 2 weeks with no improvement after a 7–10 day course of amoxicillin; recent unexplained 
weight loss/failure to thrive, fatigue/lethargy (reduced playfulness), or clinical symptoms and a history of close 
contact with an adult patient with TB, were screened for TB at admittance to the pediatric ward. Children, 
Variables of treatment response
2 months
N = 99
6 months
N = 99
Smear positivityˇ (n) 5 1
 not done 57 74
 missing 0 1
MTB culture positive° (n) 16 7
 missing 0 2
CXR
 significant clearance 37 74
 some improvement 37 19
 no improvement 23 2
 worsening 2 0
 missing 0 4
CXR recodeda 
 unfavourable 62 21
 missing 0 4
Change in Body Mass Index Z-score
 > 0 (weight gain) 80 90
 ≤ 0 (no weight gain/weight loss) 16 9
 missing 3 9
Change in weight-for-age Z-score
 > 0 (weight gain) 81 91
 ≤ 0 (no weight gain/weight loss) 18 8
 missing 0 0
Extension of ITP at 2 months 16 na
 missing 0 0
Any symptomb 24 na
 missing 0 0
Table 3.  The distribution of treatment outcomes after 2 and 6 months of antituberculosis therapy (ATT) in 
the 99 included children with intrathoracic TB. Of 2 induced sputum samples and 2 gastric aspirate samples 
taken on 2 consecutive days at least ˇone specimen positive for acid-fast bacilli, °one culture samples with 
growth of Mycobacterium tuberculosis. aAn unfavourable 2 month outcome was having either of MTB culture 
positivity, no improvement/worsening at CXR or no weight gain. An unfavourable 6 month outcome was 
having either of MTB culture positivity, lack of significant improvement at CXR or no weight gain. bAny of the 
parent-reported symptoms cough, fever, loss of appetite, weight loss, lymphnode swelling at 2 months.
www.nature.com/scientificreports/
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critically ill at admission, with significant comorbidity (including HIV), a history of anti-tuberculosis treatment 
(ATT), and/or contact with a TB case with known drug resistance were excluded. In total, 403 children with a 
diagnosis of intra-thoracic TB were included and randomly assigned to one of four groups; micronutrient supple-
mentation (MN) with or without zinc (Zn), zinc only or a placebo, initiated at the same time as ATT. Twenty-two 
children were lost to follow-up (5.5%), leaving 381 (94.5%) children who completed the 6-month follow-up.
Diagnostic assessment and follow-up. Medical history (including BCG vaccination status, history of 
TB and/or TB exposure), clinical, demographic, and anthropometric data were recorded. A TST was performed 
by a trained nurse (5 TU/0.1 mL tuberculin; Span Diagnostics, Surat, India) and read after 48–72 hours; an indu-
ration ≥ 10 mm was defined as positive. Peripheral blood (3 ml) was drawn for the QuantiFERON® -TB Gold 
In-Tube (QFT) test (Cellestis, Australia), according to the manufacturer’s instructions. A CXR, anterioposterior 
and lateral views, were recorded and interpreted by three independent radiologists. Agreement by at least two 
radiologists was required for the diagnostic inclusion criteria of intra-thoracic TB (findings of hilar or mediastinal 
adenopathy, consolidation, cavitation, miliary shadows and/or pleural effusion; criteria similar to the diagnos-
tic recommendation by the revised National Tuberculosis Control Progam of India (NTP))42. From suspected 
TB cases, gastric aspirates (GA) and induced sputa (IS) were collected on two consecutive days for fluorescent 
microscopy (Auramine) and culture (Mycobacterial Growth Indicator Tube, BD) and processed after decontami-
nation, as described previously43. The prevalence of HIV infection was assessed anonymously as part of the main 
study (TB cases only) after pretest counselling as per national guidelines44 and found to be < 1%. Children with 
HIV co-infection were excluded from the main study.
Included children were assessed every second week until 2 months of treatment and, thereafter, every 4 weeks 
until they completed the assigned ATT as per recommendation of the NTP (Category 1 treatment: isoniazid, 
rifampicin, pyrazinamide and ethambutol for 2 months followed by isoniazid and rifampicin for 4 months; 
Category 3 treatment: isoniazid, rifampicin and pyrazinamide for 2 months followed by 2 drugs for 4 months). 
Clinical and anthropometric data were recorded at every visit and CXR performed at 2 and 6 months.
Study population. Of the 403 children with intrathoracic TB included in the main study, the last 120 
included were asked to participate in the present study, which was made possible after obtaining additional 
funding and a protocol amendment. Consent to collect an additional blood draw (PAXgene Blood RNA Tubes; 
PreAnalytiX, Hilden, Germany) was given by parent/guardian for 99 of the children for one or more of the time 
points. Longitudinal samples (163 altogether) were included in the present study and assessed for transcriptional 
and translational biomarkers. Figure 1 shows the flowchart of availability of samples at each timepoint for each 
of the 4 treatment arms.
Definitions of extent of TB disease and treatment outcomes. The extent of TB disease was evalu-
ated at baseline (before the initiation of treatment) and treatment outcomes were evaluated after 2 and 6 months, 
applying established parameters known to be linked with the risk of relapse or treatment failure, namely smear 
BM entered in the 
model
Prediction by BM measured at baseline
Prediction by BM measured 
after 2 months
Prediction by the change in BM 
from baseline to 2 months
Outcome at 2 months Outcome at 6 months Outcome at 6 months Outcome at 6 months
Int. est.a Cross-validation Int. est.a Cross-validation Int. est.a Cross-validation Int. est.a Cross-validation
single biomarkers
BCL2 0,614 0,568 0,762 0,75 0,651 0,587 0,759 0,648
BLR1 0,636 0,614 0,738 0,702 0,619 0,587 0,704 0,63
CASP8 0,614 0,58 0,75 0,762 0,635 0,619 0,704 0,685
CD3E 0,636 0,568 0,726 0,714 0,651 0,587 0,741 0,667
CD4 0,602 0,545 0,714 0,679 0,603 0,556 0,685 0,63
CD19 0,625 0,557 0,762 0,714 0,651 0,587 0,667 0,667
FCGR1A 0,625 0,591 0,738 0,702 0,651 0,635 0,685 0,537
FPR1 0,625 0,58 0,75 0,714 0,651 0,603 0,722 0,667
IL7R 0,625 0,557 0,75 0,75 0,651 0,587 0,741 0,667
TGFBR2 0,614 0,591 0,75 0,75 0,651 0,571 0,704 0,574
MMP9 0,58 0,557 0,738 0,702 0,698 0,683 0,778 0,759
signatures
FCGR1A & BLR1 0,648 0,568 0,738 0,714 0,667 0,603 0,685 0,537
11 markers* 0,727 0,523 0,762 0,679 0,73 0,619 0,759 0,593
10 markers** 0,705 0,523 0,786 0,643 0,746 0,651 0,759 0,593
Table 4. The capacity to predict 2 and 6 months treatment outcomes by 11 biomarkers (BM) which 
changed consistently on ATT was analyzed applying logistic regression, leave-10-out cross-validation 
while adjusting for micronutrient supplementation. aInternal estimate of accuracy. *Cross-validation of 
the combination of all 11 biomarkers that consistently changed with treatment (BCL2, BLR1, CASP8, CD19, 
CD3E, CD4, FCGR1A, FPR1, IL7R, MMP9, and TGFBR2). **Cross-validation of the combination of the same 
markers as above, but excluding CD4. Biomarkers measured at the start of ATT (baseline), at 2 months, and the 
corresponding change in score were assessed. Prediction accuracy in the cross-validation estimates are bolded.
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positivity (in any of 2 IS or 2 GA samples), Mtb-culture positivity, cavitating disease and weight2,6,7. A favourable 
2 month outcome was defined as Mtb-culture negativity, at least some improvement on CXR and weight gain 
whereas an unfavourable outcome was having either Mtb-culture positivity, worsening or no improvement on 
CXR, or no weight gain. The outcomes at 6 months were defined similarly – the only difference being CXR for 
which a significant clearance was required for a favourable outcome. Weight change was assessed by the stand-
ardized WHO Body Mass Index-for-age Z-score (BMIZ), which was chosen over weight-for-age Z-score because 
it contains height and therefore provides more accurate information45. The change in radiological lesions was 
judged by two independent radiologists and a third radiologist was included in cases with disagreement.
RNA extraction. Total RNA was extracted from the PAXgene blood collection tubes using the ‘PAXgene 
Blood RNA kit’ with RNase free DNase on-column digestion (PreAnalytiX, Hilden, Germany) according to the 
manufacturer’s instructions. The total RNA concentration and purity (A260/280nm ratio) were measured using a 
Nanodrop spectrophotometer (Thermoscientific, Wilmington, Delaware, USA) and ranged between 0.2–13.7 μ g 
(average 2.1 ± 0.64 μ g), and supplemented by agarose gel electrophoresis.
Dual colour Reverse-Transcriptase Multiplex Ligation-dependent Probe Amplification 
(dcRT-MLPA). As available blood samples were limited, we used a novel high-throughput technique, which 
requires 130–150 ng of total RNA for a predefined panel of genes. The dcRT-MLPA method can rapidly profile 
multiple host genes with a dynamic range and sensitivity comparable to real-time qPCR and RNA sequencing at 
a cost of 5–7 euros per sample40. The genes included in the dcRT-MLPA were pre-selected based on joint efforts 
in TB biomarker discovery by the partners in Bill and Melinda Gates foundation GC6 (Supplementary Table 2)9. 
The protocol has previously been described in detail9 and therefore is only briefly discussed here. A table of 
the 49 immune-related genes analyzed for expression and their suspected relationship to TB pathogenesis have 
previously been published36 (Supplementary Table 2). Probes and primers were obtained from the Department 
of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. Primers and probes were 
synthesized by Sigma-Aldrich Chemie (Zwijndrecht, the Netherlands) and MLPA SALSA reagents were from 
MRC-Holland (Amsterdam, the Netherlands). Samples with a concentration < 50 ng/μ l were concentrated at 
45 °C using a speed-vacuum concentrator (Eppendorf AG, Hamburg, Germany). A positive control (using syn-
thetic oligonucleotides as hybridization templates) and a commercial Human Universal Reference RNA were 
included on each plate. All samples (n = 163) were run in duplicate. The amplified PCR products were diluted 
1:10 with nuclease-free H2O and added to a mixture of Hi-Di-Formamide with 400HD ROX size standard. The 
PCR fragments were denatured at 95 °C for 5 min, cooled on ice and analyzed on a 3730 capillary sequencer (Life 
Technologies, Carlsbad, California, USA). Data were analyzed using GeneMapper version 4.0 (Life Technologies, 
Carlsbad, California, USA) with adjustments of the default peak detection settings if required. The peak areas of 
replicates were averaged, normalized against GAPDH and log2 transformed as described46.
Multiplex bead array (bioplex). Biomarkers at the translational level (IFNα 2, IFNγ , IL1β , IL2, IL4, IL5, 
IL6, IL7, IL8, IL10, IL12p40, IL12p70, IL13, IL17A, IP10, MCP1, MCP3 and TNFα ) were analyzed in periph-
eral WB stimulated with MTB-specific antigens: Early Secretory Antigenic Target-6 (ESAT-6), Culture Filtrate 
Protein-10 (CFP10) and TB antigen 7.7 (QFT supernatants) and analyzed using the ‘Human cytokines 18-plex’ 
kit (Milliplex MAP Human Cytokine/Chemokine kit, Merck Millipore, Missouri, USA) according to the manu-
facturer’s instructions.
Statistical analysis. Differences in clinical characteristics between the intervention groups at baseline were 
assessed by Pearson’s chi-square test or Fisher’s exact test, where appropriate.
Treatment outcome variables were treated as binary outcomes. BMIZ was evaluated both as a binary variable 
(dichotomized around the cut-off < − 2 which marks underweight)45 and as a continuous variable.
We compared the longitudinal profiles between intervention groups after 2 and 6 months treatment by means 
of linear mixed models, which are ideally suited for analysis of repeated measurements with missing values. 
Changes in immune biomarkers over time within intervention groups were also assessed by the same models. In 
addition to the intervention-time interaction with a common baseline level, these models included adjustments 
for age and gender as fixed effects and for subject-specific differences as random effects. Measurements that fell 
below the lower detection limit or above the upper detection limit were accommodated in models as left- and 
right-censored observations, respectively47. Models were fitted to base 2 logarithm(log2)-transformed measure-
ments. Differences in mean levels were evaluated based on posthoc t-tests derived from the linear mixed models 
and reported as back-transformed fold changes.
For the biomarkers, which consistently changed with ATT, the association between their baseline levels and 
the extent of TB disease was assessed by logistic regression and Spearman’s Rank Correlation where appropri-
ate. Furthermore, values at baseline, at 2 months, and the corresponding change scores were all analyzed while 
adjusting for micronutrient supplementation by 1) separate logistic regression models to evaluate the possible 
association with the treatment outcomes at 2 and 6 months, 2) by a leave-10-out cross-validation to evaluate 
their capacity to predict the treatment outcomes at 2 and 6 months, and finally by jointly entering all transcrip-
tional biomarkers with detectable levels (20 out of 49, excluding the house-keeping gene GAPDH) into the model 
without making any a priori assumptions. All analyses were performed with and without adjustment for age at 
baseline.
The statistical environment R (R Core Team, 2014) and IBM SPSS version 21 (IBM, Bergen, Norway) 
were used for the analyses. Dot plots were created using GraphPad Prism 5 (GraphPad Software, Inc. La Jolla, 
California, USA). P-values < 0.05 were considered significant.
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Ethics statement. The study protocol was approved by the respective institutional ethics committees at the 
All India Institute of Medical Sciences, New Delhi and Kalawati Saran hospital, a children hospital associated with 
Lady Hardinge Medical College in New Delhi, India. The main randomised control trial in which this biomarker 
study is nested, was registered at clinicaltrials.gov (NCT00801606). Written informed consent was obtained from 
parents/guardians as well as written assent for participants > 7 years. All methods were performed in accordance 
with the relevant guidelines and regulations.
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